Minocycline Hydrochloride Extended-Release Tablets, USP, 105 mg*, 30-count bottle, Rx Only, Manuf...
FDA Drug Recall #D-0827-2020 — Class III — January 22, 2020
Recall Summary
| Recall Number | D-0827-2020 |
| Classification | Class III — Low risk |
| Date Initiated | January 22, 2020 |
| Status | Terminated |
| Voluntary | Voluntary: Firm initiated |
Recalling Firm
| Firm | Ascend Laboratories LLC |
| Location | Parsippany, NJ |
| Product Type | Drugs |
| Quantity | 4728 bottles |
Product Description
Minocycline Hydrochloride Extended-Release Tablets, USP, 105 mg*, 30-count bottle, Rx Only, Manufactured by: Alkem Laboratories Ltd., Mumbai - 400 013 India, Distributed by: Ascend Laboratories, LLC, Parsippany, NJ 07054, NDC 67877-438-30.
Reason for Recall
Failed Dissolution Specifications: low out of specification results for dissolution testing.
Distribution Pattern
Nationwide in the USA
Lot / Code Information
Lot #: 19140414, Exp 12/2020
Other Recalls from Ascend Laboratories LLC
| Recall # | Classification | Product | Date |
|---|---|---|---|
| D-0229-2022 | Class II | Cefixime Capsules 400 mg, 50 capsules bottles, ... | Nov 3, 2021 |
| D-0392-2021 | Class III | Olmesartan Medoxomil Tablets, USP, 20 mg, Rx On... | Apr 29, 2021 |
| D-0263-2021 | Class II | Cephalexin for Oral Suspension, USP 250 mg per ... | Jan 22, 2021 |
| D-0264-2021 | Class II | Cephalexin for Oral Suspension, USP 250 mg per ... | Jan 22, 2021 |
| D-0178-2021 | Class II | Ascend Laboratories, llc Cephalexin for Oral Su... | Dec 17, 2020 |
Frequently Asked Questions
Stop taking the medication and contact your pharmacist or doctor immediately. For Class I recalls, this is urgent. For Class II or III recalls, consult your doctor before stopping — abruptly discontinuing certain medications (blood pressure drugs, antidepressants, diabetes medications) can be more harmful than continuing while arranging a replacement. Check whether the recall applies to your specific lot number and expiration date. Return the product to your pharmacy and report any adverse effects to FDA MedWatch at 1-800-FDA-1088.
Not necessarily. Many drug recalls are initiated because of quality system failures or test results that suggest a product might not meet specifications — even if no patients have reported harm. The FDA uses a precautionary approach: if there is reason to believe quality standards were not met, a recall is required regardless of whether adverse effects have been reported. Class I recalls typically involve a reasonable probability of harm; Class II recalls may cause temporary health issues; Class III recalls are for products unlikely to cause adverse health consequences but that still violate regulations.
Pharmacies typically receive recall notices directly from drug wholesalers and manufacturers within days of the recall being announced. Your pharmacist can look up whether any product in your prescription history matches a recalled lot number. For current recalls, the FDA publishes updates at FDA.gov/safety/recalls-market-withdrawals-safety-alerts and sends MedWatch email alerts for significant drug safety issues. You can sign up for MedWatch alerts at FDA.gov. Most major pharmacy chains also have their own recall notification systems that automatically alert pharmacists when a recalled product is in their inventory.
What Should You Do?
Stop using this medication if affected by this recall. Contact your pharmacist or prescribing doctor immediately for guidance. Do not flush medications — use a drug take-back program.